ATRCNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

AtriCure, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 27, 2026

$55.53−0.54 (-0.96%)

Close on Oct 19, 2026

Market cap: $2.71B
P/E (TTM): 264.4
Dividend yield: –

Dividends

AtriCure has not reported a dividend

No dividend per share appears in AtriCure's annual filings since fiscal 2010.

Where these numbers come from

Parsed from the XBRL in AtriCure's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ATRC.

Revenue growth13.9% · median 11.8%

Gross margin76.3% · median 68.7%

Operating margin2.3% · median 4.4%

Net margin1.9% · median -0.7%

Company	Revenue	Growth
ATEC	$815.05M	+19.5%
BVS	$581.85M	+3.1%
ATRC	$569.62M	+13.9%
AORT	$471.47M	+16.4%
ANGO	$325.38M	+8.2%
LMAT	$262.43M	+11.8%

Company

Next earnings (est.): Oct 28, 2026, after close
Exchange: Nasdaq
Industry: Surgical & Medical Instruments & Apparatus
Fiscal year ends: December 31
Employees: 1,350
Held by institutions: 100.0%
Auditor: Deloitte & Touche LLP
SEC CIK: 1323885

Advertisement
300 × 250